<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Steroid-resistant nephrotic syndrome in children: Management
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Steroid-resistant nephrotic syndrome in children: Management
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Steroid-resistant nephrotic syndrome in children: Management
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Patrick Niaudet, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Olivia Gillion Boyer, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Tej K Mattoo, MD, DCH, FRCP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alison G Hoppin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 18, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H674235816">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most children with idiopathic nephrotic syndrome (NS) have minimal change disease, which is generally responsive to steroid therapy. As a result, the initial treatment for idiopathic NS is empirical steroid therapy and 80 to 90 percent of patients respond to this treatment.
        </p>
        <p>
         Steroid-resistant NS (SRNS) describes the cases that do not respond to initial steroid therapy. Approximately one-third of these cases are due to single gene variants that affect glomerular podocyte structure and/or function. These monogenic forms of SRNS are poorly responsive to immunosuppressive therapy, and disease progression is rapid. Approximately 50 percent of patients with SRNS will progress to kidney failure [
         <a href="#rid1">
          1,2
         </a>
         ]. Thus, therapeutic decisions in children with SRNS depend in part on the underlying etiology.
        </p>
        <p>
         The evaluation and management of children with SRNS will be reviewed here. Related information is available in the following topic reviews:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/16711.html" rel="external">
          "Steroid-resistant nephrotic syndrome in children: Etiology"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6130.html" rel="external">
          "Treatment of idiopathic nephrotic syndrome in children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6137.html" rel="external">
          "Congenital nephrotic syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2512246570">
         <span class="h1">
          DEFINITIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Steroid-resistant nephrotic syndrome (SRNS)
         </strong>
         – SRNS is traditionally defined as the absence of complete remission after four weeks of daily
         <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">
          prednisone
         </a>
         therapy at a dose of 60 mg/m
         <sup>
          2
         </sup>
         /day, though some patients may require additional two weeks of therapy (confirmation period) before being designated as steroid resistant [
         <a href="#rid3">
          3,4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Confirmation period
         </strong>
         – For patients who achieve only partial remission after four weeks of
         <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">
          prednisone
         </a>
         , the subsequent two weeks is known as the confirmation period. This period is used to determine their response to further interventions, such as continuation of oral prednisone and/or pulses of intravenous
         <a class="drug drug_pediatric" data-topicid="12601" href="/z/d/drug information/12601.html" rel="external">
          methylprednisolone
         </a>
         and renin-angiotensin-aldosterone system (RAAS) inhibitors [
         <a href="#rid5">
          5
         </a>
         ]. Those who achieve complete remission by six weeks are considered late responders, whereas those who are not in remission by six weeks have SRNS.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Complete remission
         </strong>
         – Resolution of proteinuria, defined as a urine protein-to-creatinine ratio of ≤20 mg/mmol (0.2 mg/mg), based on a first morning void or 24-hour collection, or urine dipstick readings of negative or trace protein on three consecutive days.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Partial remission
         </strong>
         – A decrease in proteinuria, with a urine protein-to-creatinine ratio of &gt;20 but &lt;200 mg/mmol, based on first morning void or 24-hour urine sample, and serum albumin ≥30 g/L (if measured).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Relapse
         </strong>
         – The recurrence of nephrotic-range proteinuria following either complete or partial remission.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2873485532">
         <span class="h1">
          OVERVIEW OF MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Management of SRNS involves:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genetic testing
         </strong>
         – To identify those patients with a monogenic cause of SRNS  (
         <a class="graphic graphic_table graphicRef119082" href="/z/d/graphic/119082.html" rel="external">
          table 1
         </a>
         ). The results inform decisions about immunosuppressive therapy and predict prognosis for disease progression. (See
         <a class="local">
          'Genetic testing'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immunosuppressive therapy
         </strong>
         – Most patients warrant a trial of intensified immunosuppressive therapy using a calcineurin inhibitor (CNI) [
         <a href="#rid4">
          4
         </a>
         ]. The decision depends, in part, on the results of genetic testing because the likelihood of response is greater for children without an identifiable monogenic cause of SRNS (up to 80 percent respond) compared with those with an identified monogenic cause (approximately 20 percent respond) [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If immunosuppressive therapy induces complete remission, it reduces the complications associated with NS and preserves kidney function; patients who achieve complete remission are unlikely to progress to kidney failure. These potential benefits should be weighed against the potential adverse effects of CNI, which include nephrotoxicity and infection risk. We generally avoid CNI therapy in those with congenital NS (ie, NS onset at birth or age &lt;3 months) since they are ineffective [
         <a href="#rid6">
          6
         </a>
         ] and in those with certain genotypes due to low likelihood of response and/or increased risks for adverse effects of immunosuppression. (See
         <a class="local">
          'Indications and considerations'
         </a>
         below and
         <a class="local">
          'Immunosuppressive therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antiproteinuric therapy
         </strong>
         – For patients who do not respond to the trial of CNI, therapy is directed at decreasing proteinuria using an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB), as well as management of related symptoms and complications of NS, which are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6113.html" rel="external">
          "Symptomatic management of nephrotic syndrome in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6102.html" rel="external">
          "Complications of nephrotic syndrome in children"
         </a>
         and
         <a class="local">
          'Diagnostic evaluation'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/16711.html" rel="external">
          "Steroid-resistant nephrotic syndrome in children: Etiology", section on 'Epidemiology'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Because of the complexity of decision-making and the potential for serious adverse effects of immunosuppressive agents, the care of children with SRNS should be supervised by a clinician with expertise in the management of these patients.
        </p>
        <p class="headingAnchor" id="H1713996952">
         <span class="h1">
          DIAGNOSTIC EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diagnostic evaluation, which includes genetic testing and kidney biopsy, is focused on identifying a specific cause of the SRNS when possible. The results inform selection of treatment, further evaluation, prognosis, and genetic counseling.
        </p>
        <p class="headingAnchor" id="H4090785827">
         <span class="h2">
          History and physical examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         A complete history and physical examination is performed to identify factors suggestive of an underlying monogenic etiology, including a history of family members with SRNS, history of consanguinity, and evidence on physical examination of any extrarenal or syndromic findings [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H144479144">
         <span class="h2">
          Genetic testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Monogenic causes of SRNS are listed in the table  (
         <a class="graphic graphic_table graphicRef119082" href="/z/d/graphic/119082.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/16711.html" rel="external">
          "Steroid-resistant nephrotic syndrome in children: Etiology"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H105472552">
         <span class="h3">
          Who should be tested
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest performing genetic testing for all children with SRNS if such testing is readily available, consistent with a 2020 guideline from the International Pediatric Nephrology Association (IPNA) [
         <a href="#rid4">
          4,7
         </a>
         ]. Genetic testing should preferably be performed before a kidney biopsy, provided that the genetic test results will be readily available (within a few weeks). Genetic testing is not recommended in patients who initially respond to steroids and subsequently develop steroid resistance [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         Identification of a monogenic cause of SRNS has several potential benefits [
         <a href="#rid8">
          8-13
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         It helps to avoid excessive exposure to immunosuppressive agents and their side effects because children with monogenic disease are less likely to respond.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         It avoids a diagnostic kidney biopsy in some cases.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If a syndromic form of SRNS is diagnosed, the information helps to guide further evaluation and management of extrarenal manifestations.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         It may identify a form that is amenable to an alternate (nonimmunosuppressive) treatment, ie, variants in the coenzyme Q10 (CoQ10) biosynthetic pathway [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         It informs genetic counseling, including prognosis and risk of recurrence post-transplantation. The vast majority of patients with monogenic SRNS eventually progress to kidney failure. However, if they undergo kidney transplant, their risk of disease recurrence after transplant is low. (See
         <a class="local">
          'Long-term outcome'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         If genetic testing is not readily available for all patients or where cost is an issue, we suggest that genetic screening be prioritized for patients who have an increased likelihood of an underlying genetic variant such as those with a family history of SRNS or unexplained proteinuria or hematuria, those with a history of familial consanguinity, and all patients with syndromic SRNS  (
         <a class="graphic graphic_table graphicRef107090" href="/z/d/graphic/107090.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid4">
          4,8,9,15
         </a>
         ].
        </p>
        <p>
         By contrast, genetic testing is
         <strong>
          not
         </strong>
         indicated for patients with a first episode of idiopathic NS, prior to initiation of steroid therapy. This is because more than 85 percent of children with idiopathic NS respond to steroid therapy and less than 5 percent will have a monogenic form of the disease [
         <a href="#rid10">
          10
         </a>
         ]. Earlier genetic testing is suggested only for selected patients with NS and features that suggest a hereditary cause, such as those with congenital NS (presenting before age three months) or who have syndromic features or a strong family history of NS. (See
         <a class="medical medical_review" href="/z/d/html/6101.html" rel="external">
          "Clinical manifestations, diagnosis, and evaluation of nephrotic syndrome in children", section on 'Genetic testing in selected children'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4079450593">
         <span class="h3">
          Choice of test
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Targeted gene panel
         </strong>
         – Next-generation sequencing using targeted gene panels is the preferred method for genetic testing [
         <a href="#rid4">
          4,16,17
         </a>
         ]. This technology is a rapid and efficient way to identify a disease-causing variant because it tests multiple genes simultaneously. However, it also has pitfalls and limitations because it is more likely to identify variants of uncertain clinical significance or incidental findings, which present ethical considerations [
         <a href="#rid18">
          18
         </a>
         ]. A laboratory directory lists commercial and academic laboratories throughout the world that offer molecular genetic testing at the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fgtr%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4tryNPgji1PaJ6Kbd%2Fo1hE9A6&amp;TOPIC_ID=117983" target="_blank">
          Genetic Testing Registry website
         </a>
         , which offers multiple
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fgtr%2Fall%2Ftests%2F%3Fterm%3DC0027726%255bDISCUI%255d&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4try%2FGf1ejBB10Z0hmeYYoPV71Gg7ccBqulq3sjJlp741TNJ%2FoVxYqXG%2BSK6fUQdBENE%3D&amp;TOPIC_ID=117983" target="_blank">
          gene panels related to NS
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/16711.html" rel="external">
          "Steroid-resistant nephrotic syndrome in children: Etiology"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Candidate gene testing
         </strong>
         – If next-generation sequencing is not available, a stepwise screening approach should be used to select a single gene test [
         <a href="#rid9">
          9,13
         </a>
         ]. In addition, if the presentation is suggestive of a specific monogenic form of SRNS, a targeted single gene analysis may be performed [
         <a href="#rid4">
          4
         </a>
         ]. The order of testing should be determined by the likelihood of involvement of a specific gene, as determined by the patient's characteristics (see
         <a class="medical medical_review" href="/z/d/html/16711.html" rel="external">
          "Steroid-resistant nephrotic syndrome in children: Etiology", section on 'Specific gene variants'
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Age of presentation – For younger patients, begin screening for biallelic pathogenic variants in
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F602716&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyoKfaJmD4693z9%2FLiUjVMC3&amp;TOPIC_ID=117983" target="_blank">
          <i>
           NPHS1
          </i>
         </a>
         (see
         <a class="medical medical_review" href="/z/d/html/6137.html" rel="external">
          "Congenital nephrotic syndrome"
         </a>
         ), followed by testing for
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F604766&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyrkeOQjFMq1y0JrxP8CMobC&amp;TOPIC_ID=117983" target="_blank">
          <i>
           NPHS2
          </i>
         </a>
         [
         <a href="#rid19">
          19
         </a>
         ]. For older children, screening should begin with testing for
         <em>
          NPHS2
         </em>
         variants.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Syndromic features – If syndromic features are present, prioritize testing for the compatible gene variant(s) (eg,
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F150325&amp;token=tEpDslnpc0F0kICl%2Fz7sFdq7KW313yBvat27CnEqDw826gKnW6DPmPRtpEOHLcT7&amp;TOPIC_ID=117983" target="_blank">
          <i>
           LAMB2
          </i>
         </a>
         screening for patients with ocular abnormalities and
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F607102&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdypoUP0uBoY3HY6Zw5%2B516vh&amp;TOPIC_ID=117983" target="_blank">
          <i>
           WT1
          </i>
         </a>
         screening for those with atypical genital appearance)  (
         <a class="graphic graphic_table graphicRef107090" href="/z/d/graphic/107090.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/16711.html" rel="external">
          "Steroid-resistant nephrotic syndrome in children: Etiology", section on 'Syndromic steroid-resistant nephrotic syndrome'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Histology – Test for
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F607102&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdypoUP0uBoY3HY6Zw5%2B516vh&amp;TOPIC_ID=117983" target="_blank">
          <i>
           WT1
          </i>
         </a>
         ,
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F150325&amp;token=tEpDslnpc0F0kICl%2Fz7sFdq7KW313yBvat27CnEqDw826gKnW6DPmPRtpEOHLcT7&amp;TOPIC_ID=117983" target="_blank">
          <i>
           LAMB2
          </i>
         </a>
         , and
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F608414&amp;token=tEpDslnpc0F0kICl%2Fz7sFRE1gkgqgJF7T6niZxjpYaFemxLYfgPZFw055yce0jiO&amp;TOPIC_ID=117983" target="_blank">
          <i>
           PLCE1
          </i>
         </a>
         in patients with a histologic diagnosis of diffuse mesangial sclerosis (DMS). In few cases, the findings of DMS may be associated with mutations in other genes, eg, nuclear pore (
         <em>
          NUP
         </em>
         ) genes. (See
         <a class="medical medical_review" href="/z/d/html/6137.html" rel="external">
          "Congenital nephrotic syndrome", section on 'Diffuse mesangial sclerosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4110986488">
         <span class="h2">
          Kidney biopsy
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications
         </strong>
         – We concur with the 2020 practice guidelines from the IPNA, which recommend a kidney biopsy in all children diagnosed with SRNS,
         <strong>
          except
         </strong>
         for children with [
         <a href="#rid4">
          4
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         An underlying monogenic, familial, or syndromic cause
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A secondary etiology due to an underlying infection or malignancy
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Accordingly, genetic testing should generally be performed prior to kidney biopsy when possible. However, if results from genetic testing are delayed beyond a few weeks after the diagnosis of SRNS, a kidney biopsy should be performed to provide guidance during the interim time before genetic test results are available.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Histology
         </strong>
         – If performed, the kidney biopsy provides information on the underlying histology. For children with idiopathic NS, kidney biopsy generally demonstrates four different histologic patterns:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Minimal change disease
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Diffuse mesangial proliferation
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Focal segmental glomerulosclerosis (FSGS)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         DMS
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Implications
         </strong>
         – Children with FSGS have a higher risk of kidney failure compared with those with minimal change disease [
         <a href="#rid20">
          20,21
         </a>
         ]. In the data from the PodoNet Registry, the five-year kidney failure-free survival rate was 92 percent for patients with minimal change disease and 69 percent for those with FSGS [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Histologic findings may also be characteristic of specific monogenic variants and help guide genetic testing for a specific gene variant. For example, patients with DMS should be tested for
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F607102&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdypoUP0uBoY3HY6Zw5%2B516vh&amp;TOPIC_ID=117983" target="_blank">
          <i>
           WT1
          </i>
         </a>
         ,
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F150325&amp;token=tEpDslnpc0F0kICl%2Fz7sFdq7KW313yBvat27CnEqDw826gKnW6DPmPRtpEOHLcT7&amp;TOPIC_ID=117983" target="_blank">
          <i>
           LAMB2
          </i>
         </a>
         , and
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F608414&amp;token=tEpDslnpc0F0kICl%2Fz7sFRE1gkgqgJF7T6niZxjpYaFemxLYfgPZFw055yce0jiO&amp;TOPIC_ID=117983" target="_blank">
          <i>
           PLCE1
          </i>
         </a>
         gene variants. (See
         <a class="local">
          'Choice of test'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/6137.html" rel="external">
          "Congenital nephrotic syndrome", section on 'Diffuse mesangial sclerosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Kidney biopsy results may also identify a secondary cause of NS such as lupus nephritis or membranous nephropathy that may be amenable to specific therapeutic interventions. (See
         <a class="medical medical_review" href="/z/d/html/6101.html" rel="external">
          "Clinical manifestations, diagnosis, and evaluation of nephrotic syndrome in children", section on 'Secondary nephrotic syndrome'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H589441239">
         <span class="h2">
          Screening for infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although uncommon, pediatric SRNS may be secondary to infectious diseases such as cytomegalovirus, human immunodeficiency virus (HIV), hepatitis B, malaria, parvovirus B19, syphilis, and subclinical tuberculosis. Candidates for intensified immunosuppressive therapy should have pretreatment testing for hepatitis B, hepatitis C, syphilis, and HIV and, in endemic areas, evaluation for tuberculosis [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3564807476">
         <span class="h1">
          TREATMENT
         </span>
        </p>
        <p class="headingAnchor" id="H2014339674">
         <span class="h2">
          Therapeutic options
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pharmacologic options for SRNS include [
         <a href="#rid4">
          4
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immunosuppressive therapy
         </strong>
         – For most patients with SRNS, we proceed to a trial of intensified immunosuppressive therapy, using a calcineurin inhibitor (CNI) [
         <a href="#rid4">
          4
         </a>
         ]. This therapy is most likely to be effective in those without an identified monogenic mutation, with a response rate approaching 80 percent [
         <a href="#rid15">
          15
         </a>
         ]. It is substantially less likely to be effective for children with monogenic forms of SRNS [
         <a href="#rid6">
          6,8,15,20,22,23
         </a>
         ], but a trial is still worthwhile for selected patients because up to 20 percent may respond and a favorable response delays the progression to kidney failure. (See
         <a class="local">
          'Immunosuppressive therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nonimmunologic antiproteinuric therapy
         </strong>
         – Blockade of the renin-angiotensin-aldosterone system (RAAS) with either angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) decreases proteinuria and may result in partial remission. In addition, RAAS inhibition slows the progression of chronic kidney disease (CKD). (See
         <a class="local">
          'Antiproteinuric therapy'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/6085.html" rel="external">
          "Chronic kidney disease in children: Overview of management", section on 'Reduction of proteinuria'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Coenzyme Q10 (CoQ10) supplements
         </strong>
         – These are useful only for individuals with pathogenic variants in the CoQ10 biosynthetic pathway (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F609825&amp;token=tEpDslnpc0F0kICl%2Fz7sFRE1gkgqgJF7T6niZxjpYaHp%2B5KsecK5vQopUgERZe76&amp;TOPIC_ID=117983" target="_blank">
          <i>
           COQ2
          </i>
         </a>
         ,
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F614647&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz4ktyw1uLF7dy9lVKR2v5e2&amp;TOPIC_ID=117983" target="_blank">
          <i>
           COQ6
          </i>
         </a>
         ,
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F610564&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz5o4N5IKrrMIN5A17%2B0T50K&amp;TOPIC_ID=117983" target="_blank">
          <i>
           PDSS2
          </i>
         </a>
         , and
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F615567&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz7GRekhr9aoosDLB4C%2BxaR7&amp;TOPIC_ID=117983" target="_blank">
          <i>
           COQ8B
          </i>
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1859380845">
         <span class="h2">
          Immunosuppressive therapy
         </span>
        </p>
        <p class="headingAnchor" id="H2828388350">
         <span class="h3">
          Indications and considerations
         </span>
         <span class="headingEndMark">
          —
         </span>
         The goal of intensified immunosuppressive therapy is to induce remission, thereby reducing protein excretion and the risk of complications associated with nephrosis, and to preserve kidney function. In general, immunosuppressive therapy is most likely to be effective in children with SRNS without an identified monogenic cause [
         <a href="#rid2">
          2,8,15,20,24
         </a>
         ]. The limited available evidence informs our approach, as follows  (
         <a class="graphic graphic_algorithm graphicRef129827" href="/z/d/graphic/129827.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nongenetic SRNS or genotype not available
         </strong>
         – If testing does not identify a monogenic cause of SRNS, the clinical approach depends on the patient's histologic diagnosis. It typically includes intensified immunosuppressive therapy, and subsequent steps depend on the patient's response to therapy  (
         <a class="graphic graphic_algorithm graphicRef129827" href="/z/d/graphic/129827.html" rel="external">
          algorithm 1
         </a>
         ). Although we prefer to have genetic testing results before planning therapy, the discussion below also applies if the genetic testing results are not available or are delayed. For example, in our practice, genetic testing typically takes one or two months, so we initiate immunosuppressive therapy while awaiting those results, provided that the histology results suggest that the patient may be responsive (minimal change disease or focal segmental glomerular sclerosis [FSGS] but not diffuse mesangial sclerosis [DMS]) and that kidney function is not severely impaired.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Further details about management of several specific histologic diagnoses are discussed in separate topic reviews:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3045.html" rel="external">
          "Minimal change disease: Treatment in adults", section on 'Glucocorticoid-resistant MCD'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3058.html" rel="external">
          "Membranoproliferative glomerulonephritis: Treatment and prognosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3100.html" rel="external">
          "Focal segmental glomerulosclerosis: Treatment and prognosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3051.html" rel="external">
          "Membranous nephropathy: Treatment and prognosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6137.html" rel="external">
          "Congenital nephrotic syndrome"
         </a>
         .) – Includes DMS.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6101.html" rel="external">
          "Clinical manifestations, diagnosis, and evaluation of nephrotic syndrome in children", section on 'Secondary nephrotic syndrome'
         </a>
         .) – For NS due to systemic lupus erythematosus, immunoglobulin A (IgA) nephropathy, or other causes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We use CNI therapy for immunosuppression while we taper
         <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">
          prednisone
         </a>
         therapy [
         <a href="#rid3">
          3,4
         </a>
         ]. (See
         <a class="local">
          'Implementation'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For children with severely impaired kidney function (defined as a glomerular filtration rate [GFR] &lt;30 mL/min per 1.73 m
         <sup>
          2
         </sup>
         ), our practice is to avoid immunosuppressive therapy. For these children, CNI therapy is contraindicated.
         <a class="drug drug_pediatric" data-topicid="12624" href="/z/d/drug information/12624.html" rel="external">
          Mycophenolate
         </a>
         mofetil (MMF) could be used as an alternative immunosuppressive agent, but we generally do not take this step, because these children are unlikely to have significant clinical benefit. Moreover, children with severely impaired kidney function are unlikely to experience the common complications of NS associated with significant proteinuria (eg, edema, hypogammaglobulinemia) because the loss of protein is significantly reduced with such a low GFR. (See
         <a class="local">
          'Efficacy and safety'
         </a>
         below and
         <a class="local">
          'Other immunosuppressive agents'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monogenic SRNS
         </strong>
         – Clinical decisions about treatment of monogenic SRNS are more complicated because of a substantially lower likelihood of response to intensified immunosuppressive therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For a few children with an identified monogenic cause of SRNS, we suggest a trial of a CNI (ie,
         <a class="drug drug_pediatric" data-topicid="13193" href="/z/d/drug information/13193.html" rel="external">
          cyclosporine
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12822" href="/z/d/drug information/12822.html" rel="external">
          tacrolimus
         </a>
         ) because up to 20 percent have a partial or complete response, based on limited evidence from two overlapping case series [
         <a href="#rid6">
          6,7
         </a>
         ]. We make this decision depending on the child's characteristics, using shared decision-making with the child's family. The possibility of a beneficial effect of CNI must be balanced against potential adverse effects, including nephrotoxicity (especially if given in combination with an ACE inhibitor or ARB [
         <a href="#rid25">
          25
         </a>
         ]) and infection risk. (See
         <a class="local">
          'Efficacy and safety'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         As examples:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         We are most likely to do a trial of CNI for children with rare variants such as
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F609720&amp;token=tEpDslnpc0F0kICl%2Fz7sFRE1gkgqgJF7T6niZxjpYaE7Q5C%2B%2FrvQw24oY2fr6zkB&amp;TOPIC_ID=117983" target="_blank">
          <i>
           CRB2
          </i>
         </a>
         , especially if the patient achieved partial remission during the initial course of steroids for NS.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         By contrast, we are less likely to do a trial of CNI in individuals with
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F602716&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyoKfaJmD4693z9%2FLiUjVMC3&amp;TOPIC_ID=117983" target="_blank">
          <i>
           NPHS1
          </i>
         </a>
         <em>
         </em>
         or
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F604766&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyrkeOQjFMq1y0JrxP8CMobC&amp;TOPIC_ID=117983" target="_blank">
          <i>
           NPHS2
          </i>
         </a>
         variants due to the very low response rate in these patients (2 of 58 children with these genotypes achieved complete remission in one series [
         <a href="#rid6">
          6
         </a>
         ]). We are also less likely to do a trial of CNI in individuals with a
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F606622&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyrWbatR8%2Beg7BBIX6oz42%2FW&amp;TOPIC_ID=117983" target="_blank">
          <i>
           SMARCAL1
          </i>
         </a>
         or
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F607102&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdypoUP0uBoY3HY6Zw5%2B516vh&amp;TOPIC_ID=117983" target="_blank">
          <i>
           WT1
          </i>
         </a>
         mutation due to increased risks for adverse effects of immunosuppression (marked risk of infection and risk of tumors, respectively).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         We avoid CNI in those with congenital NS (ie, NS onset at birth or age &lt;3 months) because they are very unlikely to respond (0 of 15 children in the case series [
         <a href="#rid6">
          6
         </a>
         ]).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         We do not do a trial of CNI for individuals with pathogenic variants in the CoQ10 biosynthetic pathway (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F609825&amp;token=tEpDslnpc0F0kICl%2Fz7sFRE1gkgqgJF7T6niZxjpYaHp%2B5KsecK5vQopUgERZe76&amp;TOPIC_ID=117983" target="_blank">
          <i>
           COQ2
          </i>
         </a>
         ,
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F614647&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz4ktyw1uLF7dy9lVKR2v5e2&amp;TOPIC_ID=117983" target="_blank">
          <i>
           COQ6
          </i>
         </a>
         ,
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F610564&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz5o4N5IKrrMIN5A17%2B0T50K&amp;TOPIC_ID=117983" target="_blank">
          <i>
           PDSS2
          </i>
         </a>
         , and
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F615567&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz7GRekhr9aoosDLB4C%2BxaR7&amp;TOPIC_ID=117983" target="_blank">
          <i>
           COQ8B
          </i>
         </a>
         ). Instead, we treat with the combination of a RAAS inhibitor and CoQ10 supplements. The CoQ10 dose is 5 to 30 mg/kg daily (in three divided doses) for infants and children, 300 to 1500 mg daily for adolescents, and up to 2400 mg daily for adults [
         <a href="#rid26">
          26-28
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/5149.html" rel="external">
          "Mitochondrial disorders: Treatment", section on 'CoQ10 deficiency'
         </a>
         ). Limited data from small case series suggest that this treatment is associated with reduced proteinuria and, occasionally, with complete remission [
         <a href="#rid29">
          29-32
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16711.html" rel="external">
          "Steroid-resistant nephrotic syndrome in children: Etiology", section on 'Specific gene variants'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Our suggestion to consider a trial of CNI in selected patients with monogenic SRNS is a deviation from the 2020 guidance from the International Pediatric Nephrology Association (IPNA) [
         <a href="#rid4">
          4
         </a>
         ]. This is because of new evidence from a case series in which some individuals with monogenic SRNS responded to CNI therapy (21.3 percent partial response, 6.3 percent complete response), although some of this effect may have been due to concurrent treatment with an RAAS inhibitor. (See
         <a class="local">
          'Efficacy and safety'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H426308337">
         <span class="h3">
          Implementation
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial treatment
         </strong>
         – If the decision is made to initiate CNI therapy, options are:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Cyclosporine
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="13193" href="/z/d/drug information/13193.html" rel="external">
          Cyclosporine
         </a>
         is initiated at a daily dose of 3 to 5 mg/kg/day (maximum 250 mg) divided every 12 hours. The dose is adjusted to achieve a target trough concentration of 80 to 120 ng/mL. It should not be given to patients with impaired kidney function, defined as an estimated GFR &lt;30 mL/min/1.73 m
         <sup>
          2
         </sup>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Tacrolimus
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="12822" href="/z/d/drug information/12822.html" rel="external">
          Tacrolimus
         </a>
         is initiated at a daily dose of 0.10 to 0.20 mg/kg/day (maximum 5 mg/day) divided every 12 hours. The dose is adjusted to achieve a target trough concentration between 4 and 8 ng/mL.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We give CNI in combination with
         <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">
          prednisone
         </a>
         initially, then gradually taper the prednisone for responders, as described below [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Subsequent adjustments
         </strong>
         <strong>
          of immunosuppression
         </strong>
         – For patients who respond to CNI therapy, most will do so within three months. Therapy is adjusted based on the response, as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Complete remission
         </strong>
         – For patients who enter remission with CNI therapy, the
         <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">
          prednisone
         </a>
         is tapered and discontinued after six months of sustained complete remission. If the remission continues, CNI is tapered to a minimal effective dose for 12 to 15 months and then gradually tapered off over approximately three months, as tolerated [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Partial remission
         </strong>
         – For patients with a partial response, CNI and
         <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">
          prednisone
         </a>
         doses are reduced to the lowest level needed to maintain partial remission. A repeat kidney biopsy may be indicated to detect potential development of renal interstitial fibrosis (which is irreversible) 18 to 24 months after the initiation of CNI therapy or earlier if there is a persistent deterioration of kidney function [
         <a href="#rid4">
          4
         </a>
         ]. CNI and prednisone are discontinued if there is evidence of nephrotoxicity or may be discontinued after 12 to 24 months to reduce the risk of nephrotoxicity. In these patients with partial response, MMF can be used if the CNI is being discontinued.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          No response
         </strong>
         – If there is no response after six months, CNI therapy is discontinued, usually while initiating or continuing antiproteinuric treatment. Additional options for patients with nongenetic disease include participating in a clinical trial evaluating novel potential therapies or a trial of
         <a class="drug drug_pediatric" data-topicid="12971" href="/z/d/drug information/12971.html" rel="external">
          rituximab
         </a>
         [
         <a href="#rid4">
          4
         </a>
         ]. (See
         <a class="local">
          'Other immunosuppressive agents'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Follow-up
         </strong>
         – Many patients who respond to CNI require prolonged treatment to avoid relapse [
         <a href="#rid34">
          34
         </a>
         ], which can cause irreversible renal interstitial fibrosis. In patients who require ongoing
         <a class="drug drug_pediatric" data-topicid="13193" href="/z/d/drug information/13193.html" rel="external">
          cyclosporine
         </a>
         therapy to maintain remission, we perform the following tests to monitor for nephrotoxicity:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Monitor kidney function
         </strong>
         – Serum creatinine (SCr) concentration is measured initially every three months, and, if stable, the testing is performed every six months.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Kidney biopsy
         </strong>
         – A kidney biopsy is recommended if there is an unexpected rise in SCr and prolonged partial remission. The results may inform a decision regarding changing from CNI to less nephrotoxic alternatives [
         <a href="#rid25">
          25,35
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7357.html" rel="external">
          "Cyclosporine and tacrolimus nephrotoxicity"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2335243591">
         <span class="h3">
          Efficacy and safety
         </span>
         <span class="headingEndMark">
          —
         </span>
         The above approach is based on the following evidence:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nongenetic SRNS
         </strong>
         – For patients with nongenetic SRNS, escalating immunosuppressive therapy often induces remission, based on limited evidence from observational studies [
         <a href="#rid2">
          2,15,36-40
         </a>
         ] and small randomized trials (most of which involved
         <a class="drug drug_pediatric" data-topicid="13193" href="/z/d/drug information/13193.html" rel="external">
          cyclosporine
         </a>
         and did not report genetic testing) [
         <a href="#rid41">
          41-44
         </a>
         ]. A 2019 meta-analysis found that cyclosporine compared with placebo or no treatment increased the number of children who achieved complete or partial remission (four studies, 74 participants; relative risk 3.15, 95% CI 1.04-9.57) by six months [
         <a href="#rid41">
          41
         </a>
         ]. This meta-analysis did not detect an effect of cyclosporine on progression to kidney failure. Longer-term outcomes are illustrated in an observational multicenter study of 82 such patients, in which cyclosporine induced complete remission in 49 (60 percent) and partial remission in 15 (19 percent) [
         <a href="#rid15">
          15
         </a>
         ]. Although data were not available for all patients, the median time for complete remission was 2.5 months and, for those who did not achieve complete remission, 10.5 months. At a median follow-up of 94 months, kidney function was normal for 72 percent of patients, 25 percent had progressed to kidney failure, and 3 percent developed CKD. In this study, kidney biopsy demonstrated histologic findings consistent with FSGS in 69 percent of patients with SRNS, minimal change disease in 24 percent, and diffuse mesangial proliferation in 1 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Limited data suggest that the beneficial effect of
         <a class="drug drug_pediatric" data-topicid="12822" href="/z/d/drug information/12822.html" rel="external">
          tacrolimus
         </a>
         is similar to that of
         <a class="drug drug_pediatric" data-topicid="13193" href="/z/d/drug information/13193.html" rel="external">
          cyclosporine
         </a>
         [
         <a href="#rid41">
          41,45-48
         </a>
         ]. In small clinical trials that compared tacrolimus with cyclosporine therapy in patients with SRNS, rates of remission between the two agents were similar up to two years [
         <a href="#rid46">
          46,49,50
         </a>
         ]. Some data suggest that tacrolimus has fewer adverse effects compared with cyclosporine, including less cosmetic side effects and a lower blood cholesterol level [
         <a href="#rid50">
          50
         </a>
         ]. However, tacrolimus is associated with nephrotoxicity and similar monitoring with serial measurements of SCr and periodic kidney biopsy to detect evidence of renal interstitial fibrosis. Further studies are needed to confirm whether tacrolimus offers any other advantages over cyclosporine in the management of patients with SRNS.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monogenic SRNS
         </strong>
         – Children with an identifiable monogenic cause of SRNS are less likely to respond to CNI or other escalating immunosuppressive therapy. As a result, CNI was not recommended for these children in the past [
         <a href="#rid4">
          4
         </a>
         ]. Somewhat more favorable outcomes were reported in a 2023 case series of 141 children with monogenic SRNS, in which treatment with CNI for six months was associated with complete remission in 6.3 percent and partial remission in 21.3 percent [
         <a href="#rid6">
          6
         </a>
         ]. Children with higher baseline albumin level were more likely to respond to therapy, and a favorable response to treatment was associated with a 65 percent lower risk of progressing to kidney failure at two years. In this study, no children with congenital NS achieved even partial remission [
         <a href="#rid6">
          6
         </a>
         ]. These data are consistent with other reports, some of them including the same patients [
         <a href="#rid15">
          15,20,51-53
         </a>
         ]. However, some of the partial remissions reported in these studies may have been related to concurrent treatment with RAAS inhibitors or decreased proteinuria due to progression of CKD. This might explain the appearance of more favorable outcomes compared with the PodoNet registry study, which adjusted for the latter factor [
         <a href="#rid20">
          20
         </a>
         ]. (See
         <a class="local">
          'Long-term outcome'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The partial response to CNI therapy in patients with monogenic forms of SRNS has been attributed, in part, to its nonimmunologic effects [
         <a href="#rid54">
          54
         </a>
         ]. These include antiproteinuric afferent arteriole vasoconstriction and, possibly, stabilization of the actin cytoskeleton in the podocytes and downregulation of TRPC6, a transient receptor potential channel that increases calcium influx in the podocytes.
        </p>
        <p>
        </p>
        <p>
         Nephrotoxicity is a significant adverse effect of prolonged CNI therapy and may be exacerbated with the concomitant use of an ACE inhibitor or ARB [
         <a href="#rid25">
          25
         </a>
         ]. This is a key consideration when making decisions about whether to initiate CNI therapy in children with monogenic SRNS, who are less likely to respond to CNI than those with nongenetic SRNS. If CNI therapy is used, it should be administered by a clinician with expertise in caring for children with SRNS, with close monitoring of kidney function, including measurements of SCr and serial kidney biopsies. (See
         <a class="local">
          'Indications and considerations'
         </a>
         above and
         <a class="local">
          'Implementation'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2707590451">
         <span class="h2">
          Antiproteinuric therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who continue to have persistent proteinuria, we recommend reducing protein excretion with the use of an RAAS inhibitor (ACE inhibitors or ARBs).
        </p>
        <p class="headingAnchor" id="H2293395501">
         <span class="h3">
          Efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         This recommendation is based on data from clinical trials that showed RAAS inhibition improved kidney survival in adults with proteinuria who achieve a 50 percent or greater reduction in baseline proteinuria as well as pediatric data that showed RAAS inhibition reduced protein excretion [
         <a href="#rid55">
          55-58
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7169.html" rel="external">
          "Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6085.html" rel="external">
          "Chronic kidney disease in children: Overview of management", section on 'Reduction of proteinuria'
         </a>
         .)
        </p>
        <p>
         This therapy is particularly important for patients with an identified monogenic cause of SRNS because intensified immunosuppression (eg, CNI) is often ineffective in this population. In an international registry study, treatment of children with monogenic SRNS with RAAS inhibitors for six months was associated with complete remission in 2 of 27 (7.4 percent) and partial remission in another 9 of 27 (33 percent), but 6 of 27 (22 percent) progressed to kidney failure by three years [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H614643560">
         <span class="h3">
          Implementation and timing
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Timing
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patients treated with CNI
         </strong>
         – For patients who embark on CNI therapy, it remains controversial whether antiproteinuric treatment with RAAS inhibitors (ARBs or ACE inhibitors) should be initiated sequentially or concurrently:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Sequential therapy – In our practice, we initiate CNI first (if the decision is made to try CNI therapy), then add an RAAS inhibitor after approximately three or four months if the patient has not achieved complete remission on the CNI. We use this sequential strategy because of the increased risk of nephrotoxicity when CNI and RAAS inhibitors are used concurrently [
         <a href="#rid25">
          25
         </a>
         ] and also so we can identify which drug is responsible for any response or for complications, particularly hyperkalemia or significant increase in SCr.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Concurrent therapy – Other experts in the field initiate the RAAS inhibitor and CNI treatment at the same time. The goal of this approach is to reduce proteinuria as quickly as possible and is consistent with the 2020 IPNA practice guidelines [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          No CNI treatment
         </strong>
         – If CNI is not started (eg, for most patients with monogenic SRNS), we initiate the RAAS inhibitor as soon as SRNS is diagnosed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dose and dose adjustment
         </strong>
         – Starting doses of ACE inhibitors or ARBs for treatment of proteinuria are similar to those used for treatment of hypertension  (
         <a class="graphic graphic_table graphicRef71466" href="/z/d/graphic/71466.html" rel="external">
          table 3
         </a>
         ). The dose can be advanced to the lowest effective dose to achieve complete remission of proteinuria, using caution because these patients are at risk for hyperkalemia and prerenal acute kidney injury caused by concomitant administration of a CNI or dehydration. (See
         <a class="medical medical_review" href="/z/d/html/6131.html" rel="external">
          "Nonemergent treatment of hypertension in children and adolescents", section on 'Management approach'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Safety considerations
         </strong>
         – Female patients of childbearing age must be counseled regarding the teratogenic effects of ACE inhibitors and ARBs prior to initiation of therapy. ACE inhibitors and ARBs should be terminated if hyperkalemia cannot be controlled or the plasma creatinine concentration increases more than 30 percent above the baseline value. (See
         <a class="medical medical_review" href="/z/d/html/4789.html" rel="external">
          "Adverse effects of angiotensin converting enzyme inhibitors and receptor blockers in pregnancy", section on 'Clinical approach to use of RAAS inhibitors in females of childbearing potential'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2145392182">
         <span class="h2">
          Blood pressure management
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypertension is more commonly seen in patients with SRNS than those with steroid-sensitive disease [
         <a href="#rid3">
          3
         </a>
         ]. For children with CKD including NS, aggressive blood pressure (BP) control slows the progression of CKD. In these patients, targeted BP goals are systolic and diastolic BPs of &lt;90
         <sup>
          th
         </sup>
         percentile for age, sex, and height based on office BP measurements and, in adolescents (≥13 years of age), a target BP of ≤120/80 mmHg  (
         <a class="graphic graphic_table graphicRef129760" href="/z/d/graphic/129760.html" rel="external">
          table 4
         </a>
         ). Hypertension is defined as BP greater than the targeted goal on three occasions. If ambulatory BP monitoring is available, the targeted BP goal is a mean arterial BP &lt;50
         <sup>
          th
         </sup>
         percentile based on 24-hour monitoring.
        </p>
        <p>
         BP management consists of:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nonpharmacologic measures
         </strong>
         – This includes weight reduction for children with overweight, a regular aerobic exercise regimen (ie, &gt;30 minutes of at least moderate exercise at least five days per week); dietary measures (eg, diet rich in fruit/vegetables and reduced fat and salt intake); and avoidance of excessive alcohol consumption, caffeine, energy drinks, and smoke exposure.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pharmacologic therapy
         </strong>
         – For children with hypertension despite nonpharmacologic measures, we suggest initiating pharmacologic therapy, using ACE inhibitors or ARBs rather than other antihypertensive agents as they provide the additional benefit of reducing proteinuria.
        </p>
        <p>
        </p>
        <p>
         Hypertension and its management in children with CKD are discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/128353.html" rel="external">
          "Chronic kidney disease in children: Complications", section on 'Hypertension'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4137354125">
         <span class="h2">
          Other immunosuppressive agents
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          MMF
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="12624" href="/z/d/drug information/12624.html" rel="external">
          Mycophenolate
         </a>
         mofetil (MMF) is a second-line agent for treating children with SRNS because the available evidence regarding its efficacy is limited and inconsistent [
         <a href="#rid33">
          33,59-64
         </a>
         ]. MMF be used for patients who respond partially to CNI but require an alternative therapy because of concerns about nephrotoxicity [
         <a href="#rid4">
          4,33,61,63
         </a>
         ]. Some centers use MMF as initial therapy for children with SRNS and severe kidney function impairment (GFR &lt;30 mL/min per 1.73 m
         <sup>
          2
         </sup>
         ) [
         <a href="#rid4">
          4
         </a>
         ]. However, we generally avoid all immunosuppressive therapy in children with severely impaired kidney function because their low GFR protects them from complications of nephrosis. If MMF is used, the suggested dose is 1200 mg/m
         <sup>
          2
         </sup>
         daily (maximum daily dose 2000 mg/day), with subsequent dose adjustments based on therapeutic drug monitoring, aiming for an area under the curve &gt;50 micrograms × hour/mL [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rituximab
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="12971" href="/z/d/drug information/12971.html" rel="external">
          Rituximab
         </a>
         is a second-line agent for treating children with SRNS due to limited evidence demonstrating its efficacy and safety in this population. Reported adverse effects include infusion-related reactions (hypotension, fever, and rigors), serious infections, and progressive multifocal leukoencephalopathy. One published report described the death of a child with NS due to lung fibrosis [
         <a href="#rid65">
          65,66
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1694.html" rel="external">
          "Progressive multifocal leukoencephalopathy (PML): Epidemiology, clinical manifestations, and diagnosis", section on 'Immunomodulatory therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Published data continue to accumulate but are primarily based on case series, which have mixed patient populations, including patients who were initially responsive to steroids and subsequently developed steroid resistance (late), as well as those with initial steroid resistance. These data were summarized by a systematic review performed before April 2017, which included seven case series and one open-label clinical trial with a total of 226 patients [
         <a href="#rid67">
          67
         </a>
         ]. For the group of patients who were initially resistant to steroids (n = 165 patients), the rate of complete or partial remission was 42 percent. Of note, in the only included clinical trial, the remission rate was only 19 percent. Serious adverse events occurred in five patients and included agranulocytosis, severe pneumonia due to influenza H1N1 virus, cardiomyopathy, rapid progression to kidney failure, and pancolitis. Other adverse effects included infusion-related fever, abdominal pain, diarrhea, vomiting, skin rash, bronchospasm, tachycardia, and hypertension.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         These data confirm our recommendation not to routinely use
         <a class="drug drug_pediatric" data-topicid="12971" href="/z/d/drug information/12971.html" rel="external">
          rituximab
         </a>
         in the treatment of SRNS until further evidence demonstrates a degree of efficacy that outweighs the potential adverse effects of this drug.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Combination immunosuppressive therapy
         </strong>
         – Combination immunosuppressive regimens have been tried in relatively small numbers of patients [
         <a href="#rid33">
          33,68-74
         </a>
         ]. Data are too limited to determine whether these therapies were efficacious and safe. As a result, we do not recommend these regimens, because the potential limited benefit is outweighed by the significant adverse events associated with these therapeutic agents. However, patients with multidrug resistance are encouraged to participate in clinical trials of various drugs and extracorporeal interventions (eg, plasmapheresis, immunoadsorption) for SRNS. An updated list of active glomerular disease trials is available through
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fkidneyhealthgateway.com%2Ftrials-research%2F&amp;token=waXqRhPbQ7Y7iNvb5%2ByvVLab0I9fIgaEJ5ZZHuqTQJ1TZF2QlkezdBxmwfBFF66m2hSc2F%2BDKYAz88D2aY%2FDpQ%3D%3D&amp;TOPIC_ID=117983" target="_blank">
          NephCure Kidney International
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Alkylating agents
         </strong>
         – There are no data showing a beneficial effect of alkylating agents in children with SRNS. Partial or complete remissions have been reported in 20 to 50 percent of cases following a course of
         <a class="drug drug_pediatric" data-topicid="13191" href="/z/d/drug information/13191.html" rel="external">
          cyclophosphamide
         </a>
         , but this is based on small studies; the lower end of the range is similar to the remission rate of nontreated patients or that of those who continue to receive steroid therapy alone [
         <a href="#rid41">
          41,44,75-78
         </a>
         ]. Because of its low efficacy in SRNS and substantial toxicity, we do not recommend use of alkylating agents in patients with SRNS [
         <a href="#rid79">
          79
         </a>
         ]. Although the 2020 IPNA guidelines suggest that cyclophosphamide (an oral alkylating agent) may be offered to patients when CNI is not available (ie, in low-resource settings), they also note that cyclophosphamide offered no additional benefit compared with steroids alone [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3303878814">
         <span class="h1">
          LONG-TERM OUTCOME
         </span>
         <span class="headingEndMark">
          —
         </span>
         Data are limited regarding long-term outcome for children with SRNS. The best available long-term data are from a review of 1354 children with SRNS in the PodoNet Registry [
         <a href="#rid20">
          20
         </a>
         ]. The overall kidney failure-free survival rates were 74 percent (95% CI 71-77 percent) at 5 years, 58 percent (95% CI 53-61 percent) at 10 years, and 48 percent (95% CI 43-53 percent) at 15 years. Risk factors for kidney failure included:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Known monogenic variant
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Failure to respond to intensified immunosuppressive therapy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Histologic diagnosis of diffuse mesangial sclerosis (DMS) or focal segmental glomerulosclerosis (FSGS)
        </p>
        <p>
        </p>
        <p>
         Complete remission of proteinuria was observed in 25 percent of patients, with the highest rates of complete or partial remission associated with calcineurin inhibitors (CNIs) [
         <a href="#rid20">
          20
         </a>
         ]. Of the 74 patients diagnosed with a genetic variant who received intensified immunosuppressive therapy, only two responded transiently to immunosuppressive therapy (
         <a class="drug drug_pediatric" data-topicid="13193" href="/z/d/drug information/13193.html" rel="external">
          cyclosporine
         </a>
         ), one of whom progressed to kidney failure within five years. A somewhat higher remission rate was reported in a separate study (21.3 percent partial response, 6.3 percent complete response), but this may have been related to concurrent treatment with renin-angiotensin-aldosterone system (RAAS) inhibitors or shorter follow-up or because it did not distinguish between true partial remission and decreased proteinuria due to progression of chronic kidney disease (CKD) [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         Similar results were also seen in an analysis of the United Kingdom National Registry of Rare Kidney Diseases [
         <a href="#rid7">
          7
         </a>
         ]. In this smaller cohort of 271 children with SRNS, patients who had a complete remission rarely progressed to kidney failure. Those with monogenic SRNS typically were unresponsive and likely to progress to kidney failure but did not have recurrence following kidney transplantation, whereas nonresponders without an underlying monogenic etiology had poor kidney survival after transplantation and a high post-transplant rate of disease recurrence.
        </p>
        <p class="headingAnchor" id="H3082854293">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110405.html" rel="external">
          "Society guideline links: Nephrotic syndrome in children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1925146904">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definitions
         </strong>
         – Steroid-resistant nephrotic syndrome (SRNS) is defined as the absence of remission after four weeks of initial daily
         <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">
          prednisone
         </a>
         therapy at a dose of 60 mg/m
         <sup>
          2
         </sup>
         /day. (See
         <a class="local">
          'Definitions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnostic evaluation
         </strong>
         – Diagnostic evaluation for SRNS generally includes genetic testing, kidney biopsy, and screening for secondary causes of SRNS (infection, malignancy, or autoimmune disease). The results inform selection of treatment, further evaluation, prognosis, and genetic counseling. (See
         <a class="local">
          'Diagnostic evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Genetic testing
         </strong>
         – All patients with SRNS should have genetic testing for a panel of genetic variants known to cause SRNS  (
         <a class="graphic graphic_table graphicRef119082" href="/z/d/graphic/119082.html" rel="external">
          table 1
         </a>
         ). The results help to determine the likelihood of responding to intensified immunosuppressive therapy, as well as overall prognosis. A less preferred approach is to prioritize genetic testing for patients with features suggesting monogenic SRNS, including those with congenital or syndromic SRNS  (
         <a class="graphic graphic_table graphicRef107090" href="/z/d/graphic/107090.html" rel="external">
          table 2
         </a>
         ), a family history of SRNS or unexplained proteinuria, or consanguinity. (See
         <a class="local">
          'Genetic testing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Kidney biopsy
         </strong>
         – If genetic screening is not performed or does not identify a monogenic etiology, or the results are delayed beyond two weeks, most patients should have a kidney biopsy to determine the underlying histology. A biopsy may not be needed in patients with an identified monogenic or secondary cause. The results of a kidney biopsy may demonstrate secondary causes that are amenable to therapy, or idiopathic NS (ie, minimal change disease, diffuse mesangial proliferation, or focal segmental sclerosis [FSGS]). If one of these histologic patterns is identified, we suggest genetic testing, if not already done. (See
         <a class="local">
          'Kidney biopsy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Immunosuppressive therapy
         </strong>
         – Decisions about intensified immunosuppressive therapy depend, in part, on results of genetic testing:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Nongenetic SRNS
         </strong>
         – For patients with SRNS and no identifiable monogenic cause, we suggest a trial of intensified immunosuppressive therapy with a calcineurin inhibitor (CNI; ie,
         <a class="drug drug_pediatric" data-topicid="13193" href="/z/d/drug information/13193.html" rel="external">
          cyclosporine
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12822" href="/z/d/drug information/12822.html" rel="external">
          tacrolimus
         </a>
         ) rather than no immunosuppressive therapy (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ) and rather than other immunosuppressive agents (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). If immunosuppressive therapy is successful, it reduces the complications associated with NS and preserves kidney function. These potential benefits should be weighed against the potential adverse effects of CNI, which include nephrotoxicity and infection risk. Most children without an identifiable monogenic cause of SRNS respond to CNI (up to 80 percent). (See
         <a class="local">
          'Immunosuppressive therapy'
         </a>
         above and
         <a class="local">
          'Efficacy and safety'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Genetic SRNS
         </strong>
         – For most patients with SRNS with a monogenic cause, we suggest
         <strong>
          against
         </strong>
         intensified immunosuppressive therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). For most monogenic causes, response rates to CNI are low and intensified immunosuppression is associated with increased risk for adverse effects. However, decisions for this group are complex and depend on the genotype. A rare exception is the patient with a
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F609720&amp;token=tEpDslnpc0F0kICl%2Fz7sFRE1gkgqgJF7T6niZxjpYaE7Q5C%2B%2FrvQw24oY2fr6zkB&amp;TOPIC_ID=117983" target="_blank">
          <i>
           CRB2
          </i>
         </a>
         variant, for whom we may trial CNI therapy, especially if the patient achieved partial remission during the initial course of steroids for NS. We do
         <strong>
          not
         </strong>
         use CNI therapy for children with congenital NS (age of onset &lt;3 months), severely impaired kidney function, or biallelic pathogenic variants in the coenzyme Q10 (CoQ10) biosynthetic pathway. (See
         <a class="local">
          'Immunosuppressive therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Nonimmunologic antiproteinuric therapy
         </strong>
         – For patients who are not candidates for CNI therapy (ie, most patients with a monogenic cause of SRNS), and for those treated with CNI therapy who do not achieve complete remission after approximately three or four months, we suggest adding a renin-angiotensin-aldosterone system (RAAS) inhibitor (either an angiotensin-converting enzyme [ACE] inhibitor or angiotensin II receptor blocker [ARB]) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Blockade of the RAAS system decreases proteinuria and may result in partial remission. Practice varies regarding the sequencing of these therapies. Our practice is to add the RAAS inhibitor after the CNI in an effort to reduce the risk of additive nephrotoxic effects. Other experts initiate both therapies simultaneously in an attempt to increase the likelihood of remission. (See
         <a class="local">
          'Antiproteinuric therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          CoQ10 therapy
         </strong>
         – For individuals with biallelic pathogenic variants in the CoQ10 biosynthetic pathway, we suggest treatment with CoQ10 supplements and an RAAS inhibitor, rather than immunosuppressive therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Indications and considerations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Blood pressure (BP) management
         </strong>
         – In all children with SRNS, elevated BP should be aggressively treated as aggressive BP control slows the progression of chronic kidney disease (CKD). BP management includes nonpharmacologic measures and pharmacologic treatment. If antihypertensive therapy is necessary, ACE inhibitors or ARBs are generally the preferred agents since they reduce proteinuria. BP targets are summarized in the table  (
         <a class="graphic graphic_table graphicRef129760" href="/z/d/graphic/129760.html" rel="external">
          table 4
         </a>
         ). BP management in children with CKD is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/128353.html" rel="external">
          "Chronic kidney disease in children: Complications", section on 'Hypertension'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – Approximately one-half of children with SRNS progress to kidney failure within 15 years. Risk factors for disease progression include a monogenic diagnosis, failure to respond to intensified immunosuppressive therapy, and a histologic diagnosis of diffuse mesangial sclerosis (DMS). (See
         <a class="local">
          'Long-term outcome'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H614174407">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges William Smoyer, MD, FASN, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr. Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. J Am Soc Nephrol 1997; 8:769.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ehrich JH, Geerlings C, Zivicnjak M, et al. Steroid-resistant idiopathic childhood nephrosis: overdiagnosed and undertreated. Nephrol Dial Transplant 2007; 22:2183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children. J Pediatr 1981; 98:561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trautmann A, Vivarelli M, Samuel S, et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 2020; 35:1529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trautmann A, Seide S, Lipska-Ziętkiewicz BS, et al. Outcomes of steroid-resistant nephrotic syndrome in children not treated with intensified immunosuppression. Pediatr Nephrol 2023; 38:1499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malakasioti G, Iancu D, Milovanova A, et al. A multicenter retrospective study of calcineurin inhibitors in nephrotic syndrome secondary to podocyte gene variants. Kidney Int 2023; 103:962.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mason AE, Sen ES, Bierzynska A, et al. Response to First Course of Intensified Immunosuppression in Genetically Stratified Steroid Resistant Nephrotic Syndrome. Clin J Am Soc Nephrol 2020; 15:983.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Büscher AK, Kranz B, Büscher R, et al. Immunosuppression and renal outcome in congenital and pediatric steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol 2010; 5:2075.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santín S, Bullich G, Tazón-Vega B, et al. Clinical utility of genetic testing in children and adults with steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol 2011; 6:1139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Niaudet P. Podocin and nephrotic syndrome: implications for the clinician. J Am Soc Nephrol 2004; 15:832.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruf RG, Schultheiss M, Lichtenberger A, et al. Prevalence of WT1 mutations in a large cohort of patients with steroid-resistant and steroid-sensitive nephrotic syndrome. Kidney Int 2004; 66:564.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Niaudet P. Genetic forms of nephrotic syndrome. Pediatr Nephrol 2004; 19:1313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benoit G, Machuca E, Antignac C. Hereditary nephrotic syndrome: a systematic approach for genetic testing and a review of associated podocyte gene mutations. Pediatr Nephrol 2010; 25:1621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lovric S, Ashraf S, Tan W, Hildebrandt F. Genetic testing in steroid-resistant nephrotic syndrome: when and how? Nephrol Dial Transplant 2016; 31:1802.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Büscher AK, Beck BB, Melk A, et al. Rapid Response to Cyclosporin A and Favorable Renal Outcome in Nongenetic Versus Genetic Steroid-Resistant Nephrotic Syndrome. Clin J Am Soc Nephrol 2016; 11:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lovric S, Fang H, Vega-Warner V, et al. Rapid detection of monogenic causes of childhood-onset steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol 2014; 9:1109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sen ES, Dean P, Yarram-Smith L, et al. Clinical genetic testing using a custom-designed steroid-resistant nephrotic syndrome gene panel: analysis and recommendations. J Med Genet 2017; 54:795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weber S, Büscher AK, Hagmann H, et al. Dealing with the incidental finding of secondary variants by the example of SRNS patients undergoing targeted next-generation sequencing. Pediatr Nephrol 2016; 31:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17:405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trautmann A, Schnaidt S, Lipska-Ziętkiewicz BS, et al. Long-Term Outcome of Steroid-Resistant Nephrotic Syndrome in Children. J Am Soc Nephrol 2017; 28:3055.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Waldherr R, Gubler MC, Levy M, et al. The significance of pure diffuse mesangial proliferation in idiopathic nephrotic syndrome. Clin Nephrol 1978; 10:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schulman SL, Kaiser BA, Polinsky MS, et al. Predicting the response to cytotoxic therapy for childhood nephrotic syndrome: superiority of response to corticosteroid therapy over histopathologic patterns. J Pediatr 1988; 113:996.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malina M, Cinek O, Janda J, Seeman T. Partial remission with cyclosporine A in a patient with nephrotic syndrome due to NPHS2 mutation. Pediatr Nephrol 2009; 24:2051.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruf RG, Lichtenberger A, Karle SM, et al. Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome. J Am Soc Nephrol 2004; 15:722.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kengne-Wafo S, Massella L, Diomedi-Camassei F, et al. Risk factors for cyclosporin A nephrotoxicity in children with steroid-dependant nephrotic syndrome. Clin J Am Soc Nephrol 2009; 4:1409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rötig A, Appelkvist EL, Geromel V, et al. Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency. Lancet 2000; 356:391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salviati L, Sacconi S, Murer L, et al. Infantile encephalomyopathy and nephropathy with CoQ10 deficiency: a CoQ10-responsive condition. Neurology 2005; 65:606.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang Y, Hekimi S. The efficacy of coenzyme Q10 treatment in alleviating the symptoms of primary coenzyme Q10 deficiency: A systematic review. J Cell Mol Med 2022; 26:4635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montini G, Malaventura C, Salviati L. Early coenzyme Q10 supplementation in primary coenzyme Q10 deficiency. N Engl J Med 2008; 358:2849.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stańczyk M, Bałasz-Chmielewska I, Lipska-Ziętkiewicz B, Tkaczyk M. CoQ10-related sustained remission of proteinuria in a child with COQ6 glomerulopathy-a case report. Pediatr Nephrol 2018; 33:2383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Atmaca M, Gulhan B, Korkmaz E, et al. Follow-up results of patients with ADCK4 mutations and the efficacy of CoQ10 treatment. Pediatr Nephrol 2017; 32:1369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan W, Airik R. Primary coenzyme Q10 nephropathy, a potentially treatable form of steroid-resistant nephrotic syndrome. Pediatr Nephrol 2021; 36:3515.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gipson DS, Trachtman H, Kaskel FJ, et al. Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int 2011; 80:868.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamasaki Y, Yoshikawa N, Nakazato H, et al. Prospective 5-year follow-up of cyclosporine treatment in children with steroid-resistant nephrosis. Pediatr Nephrol 2013; 28:765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Habib R, Niaudet P. Comparison between pre- and posttreatment renal biopsies in children receiving ciclosporine for idiopathic nephrosis. Clin Nephrol 1994; 42:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahmoud I, Basuni F, Sabry A, et al. Single-centre experience with cyclosporin in 106 children with idiopathic focal segmental glomerulosclerosis. Nephrol Dial Transplant 2005; 20:735.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Niaudet P. Treatment of childhood steroid-resistant idiopathic nephrosis with a combination of cyclosporine and prednisone. French Society of Pediatric Nephrology. J Pediatr 1994; 125:981.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gregory MJ, Smoyer WE, Sedman A, et al. Long-term cyclosporine therapy for pediatric nephrotic syndrome: a clinical and histologic analysis. J Am Soc Nephrol 1996; 7:543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ingulli E, Singh A, Baqi N, et al. Aggressive, long-term cyclosporine therapy for steroid-resistant focal segmental glomerulosclerosis. J Am Soc Nephrol 1995; 5:1820.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chishti AS, Sorof JM, Brewer ED, Kale AS. Long-term treatment of focal segmental glomerulosclerosis in children with cyclosporine given as a single daily dose. Am J Kidney Dis 2001; 38:754.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu ID, Willis NS, Craig JC, Hodson EM. Interventions for idiopathic steroid-resistant nephrotic syndrome in children. Cochrane Database Syst Rev 2019; 2019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ponticelli C, Edefonti A, Ghio L, et al. Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial. Nephrol Dial Transplant 1993; 8:1326.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lieberman KV, Tejani A. A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. J Am Soc Nephrol 1996; 7:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Plank C, Kalb V, Hinkes B, et al. Cyclosporin A is superior to cyclophosphamide in children with steroid-resistant nephrotic syndrome-a randomized controlled multicentre trial by the Arbeitsgemeinschaft für Pädiatrische Nephrologie. Pediatr Nephrol 2008; 23:1483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gulati S, Prasad N, Sharma RK, et al. Tacrolimus: a new therapy for steroid-resistant nephrotic syndrome in children. Nephrol Dial Transplant 2008; 23:910.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choudhry S, Bagga A, Hari P, et al. Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial. Am J Kidney Dis 2009; 53:760.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roberti I, Vyas S. Long-term outcome of children with steroid-resistant nephrotic syndrome treated with tacrolimus. Pediatr Nephrol 2010; 25:1117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Butani L, Ramsamooj R. Experience with tacrolimus in children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 2009; 24:1517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang W, Xia Y, Mao J, et al. Treatment of tacrolimus or cyclosporine A in children with idiopathic nephrotic syndrome. Pediatr Nephrol 2012; 27:2073.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prasad N, Manjunath R, Rangaswamy D, et al. Efficacy and Safety of Cyclosporine versus Tacrolimus in Steroid and Cyclophosphamide Resistant Nephrotic Syndrome: A Prospective Study. Indian J Nephrol 2018; 28:46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stefanidis CJ, Querfeld U. The podocyte as a target: cyclosporin A in the management of the nephrotic syndrome caused by WT1 mutations. Eur J Pediatr 2011; 170:1377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wasilewska AM, Kuroczycka-Saniutycz E, Zoch-Zwierz W. Effect of cyclosporin A on proteinuria in the course of glomerulopathy associated with WT1 mutations. Eur J Pediatr 2011; 170:389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malakasioti G, Iancu D, Tullus K. Calcineurin inhibitors in nephrotic syndrome secondary to podocyte gene mutations: a systematic review. Pediatr Nephrol 2021; 36:1353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bensman A, Niaudet P. Non-immunologic mechanisms of calcineurin inhibitors explain its antiproteinuric effects in genetic glomerulopathies. Pediatr Nephrol 2010; 25:1197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montané B, Abitbol C, Chandar J, et al. Novel therapy of focal glomerulosclerosis with mycophenolate and angiotensin blockade. Pediatr Nephrol 2003; 18:772.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ellis D, Vats A, Moritz ML, et al. Long-term antiproteinuric and renoprotective efficacy and safety of losartan in children with proteinuria. J Pediatr 2003; 143:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bagga A, Mudigoudar BD, Hari P, Vasudev V. Enalapril dosage in steroid-resistant nephrotic syndrome. Pediatr Nephrol 2004; 19:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yi Z, Li Z, Wu XC, et al. Effect of fosinopril in children with steroid-resistant idiopathic nephrotic syndrome. Pediatr Nephrol 2006; 21:967.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cattran DC, Wang MM, Appel G, et al. Mycophenolate mofetil in the treatment of focal segmental glomerulosclerosis. Clin Nephrol 2004; 62:405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mendizábal S, Zamora I, Berbel O, et al. Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome. Pediatr Nephrol 2005; 20:914.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gargah TT, Lakhoua MR. Mycophenolate mofetil in treatment of childhood steroid-resistant nephrotic syndrome. J Nephrol 2011; 24:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Mello VR, Rodrigues MT, Mastrocinque TH, et al. Mycophenolate mofetil in children with steroid/cyclophosphamide-resistant nephrotic syndrome. Pediatr Nephrol 2010; 25:453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li Z, Duan C, He J, et al. Mycophenolate mofetil therapy for children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 2010; 25:883.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sinha A, Gupta A, Kalaivani M, et al. Mycophenolate mofetil is inferior to tacrolimus in sustaining remission in children with idiopathic steroid-resistant nephrotic syndrome. Kidney Int 2017; 92:248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pradhan M, Furth S. Rituximab in steroid-resistant nephrotic syndrome in children: a (false) glimmer of hope? J Am Soc Nephrol 2012; 23:975.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chaumais MC, Garnier A, Chalard F, et al. Fatal pulmonary fibrosis after rituximab administration. Pediatr Nephrol 2009; 24:1753.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jellouli M, Charfi R, Maalej B, et al. Rituximab in The Management of Pediatric Steroid-Resistant Nephrotic Syndrome: A Systematic Review. J Pediatr 2018; 197:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Basu B, Mahapatra TK, Mondal N. Mycophenolate Mofetil Following Rituximab in Children With Steroid-Resistant Nephrotic Syndrome. Pediatrics 2015; 136:e132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nattes E, Karaa D, Dehoux L, et al. Remission of proteinuria in multidrug-resistant idiopathic nephrotic syndrome following immunoglobulin immunoadsorption. Acta Paediatr 2019; 108:757.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aizawa-Yashiro T, Tsuruga K, Watanabe S, et al. Novel multidrug therapy for children with cyclosporine-resistant or -intolerant nephrotic syndrome. Pediatr Nephrol 2011; 26:1255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tune BM, Mendoza SA. Treatment of the idiopathic nephrotic syndrome: regimens and outcomes in children and adults. J Am Soc Nephrol 1997; 8:824.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mendoza SA, Reznik VM, Griswold WR, et al. Treatment of steroid-resistant focal segmental glomerulosclerosis with pulse methylprednisolone and alkylating agents. Pediatr Nephrol 1990; 4:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tune BM, Kirpekar R, Sibley RK, et al. Intravenous methylprednisolone and oral alkylating agent therapy of prednisone-resistant pediatric focal segmental glomerulosclerosis: a long-term follow-up. Clin Nephrol 1995; 43:84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kamei K, Okada M, Sato M, et al. Rituximab treatment combined with methylprednisolone pulse therapy and immunosuppressants for childhood steroid-resistant nephrotic syndrome. Pediatr Nephrol 2014; 29:1181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr. Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis. A report of the International Study of Kidney Disease in Children. Pediatr Nephrol 1996; 10:590.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gulati A, Sinha A, Gupta A, et al. Treatment with tacrolimus and prednisolone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome. Kidney Int 2012; 82:1130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geary DF, Farine M, Thorner P, Baumal R. Response to cyclophosphamide in steroid-resistant focal segmental glomerulosclerosis: a reappraisal. Clin Nephrol 1984; 22:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mattoo TK. Kidney biopsy prior to cyclophosphamide therapy in primary nephrotic syndrome. Pediatr Nephrol 1991; 5:617.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lombel RM, Hodson EM, Gipson DS, Kidney Disease: Improving Global Outcomes. Treatment of steroid-resistant nephrotic syndrome in children: new guidelines from KDIGO. Pediatr Nephrol 2013; 28:409.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 117983 Version 26.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9176846" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17504846" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Steroid-resistant idiopathic childhood nephrosis: overdiagnosed and undertreated.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7205481" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32382828" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36315273" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Outcomes of steroid-resistant nephrotic syndrome in children not treated with intensified immunosuppression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36898413" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : A multicenter retrospective study of calcineurin inhibitors in nephrotic syndrome secondary to podocyte gene variants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32317330" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Response to First Course of Intensified Immunosuppression in Genetically Stratified Steroid Resistant Nephrotic Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20798252" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Immunosuppression and renal outcome in congenital and pediatric steroid-resistant nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21415313" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Clinical utility of genetic testing in children and adults with steroid-resistant nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14978189" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Podocin and nephrotic syndrome: implications for the clinician.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15253707" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Prevalence of WT1 mutations in a large cohort of patients with steroid-resistant and steroid-sensitive nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15503167" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Genetic forms of nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20333530" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Hereditary nephrotic syndrome: a systematic approach for genetic testing and a review of associated podocyte gene mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26507970" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Genetic testing in steroid-resistant nephrotic syndrome: when and how?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26668027" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Rapid Response to Cyclosporin A and Favorable Renal Outcome in Nongenetic Versus Genetic Steroid-Resistant Nephrotic Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24742477" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Rapid detection of monogenic causes of childhood-onset steroid-resistant nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28780565" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Clinical genetic testing using a custom-designed steroid-resistant nephrotic syndrome gene panel: analysis and recommendations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26248470" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Dealing with the incidental finding of secondary variants by the example of SRNS patients undergoing targeted next-generation sequencing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25741868" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28566477" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Long-Term Outcome of Steroid-Resistant Nephrotic Syndrome in Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/365403" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : The significance of pure diffuse mesangial proliferation in idiopathic nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3193322" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Predicting the response to cytotoxic therapy for childhood nephrotic syndrome: superiority of response to corticosteroid therapy over histopathologic patterns.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19495806" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Partial remission with cyclosporine A in a patient with nephrotic syndrome due to NPHS2 mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14978175" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19628686" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Risk factors for cyclosporin A nephrotoxicity in children with steroid-dependant nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10972372" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16116126" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Infantile encephalomyopathy and nephropathy with CoQ10 deficiency: a CoQ10-responsive condition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35985679" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : The efficacy of coenzyme Q10 treatment in alleviating the symptoms of primary coenzyme Q10 deficiency: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18579827" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Early coenzyme Q10 supplementation in primary coenzyme Q10 deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30232548" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : CoQ10-related sustained remission of proteinuria in a child with COQ6 glomerulopathy-a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28337616" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Follow-up results of patients with ADCK4 mutations and the efficacy of CoQ10 treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33479824" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Primary coenzyme Q10 nephropathy, a potentially treatable form of steroid-resistant nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21734640" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Clinical trial of focal segmental glomerulosclerosis in children and young adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23314441" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Prospective 5-year follow-up of cyclosporine treatment in children with steroid-resistant nephrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7994931" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Comparison between pre- and posttreatment renal biopsies in children receiving ciclosporine for idiopathic nephrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15772265" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Single-centre experience with cyclosporin in 106 children with idiopathic focal segmental glomerulosclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7996374" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Treatment of childhood steroid-resistant idiopathic nephrosis with a combination of cyclosporine and prednisone. French Society of Pediatric Nephrology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8724887" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Long-term cyclosporine therapy for pediatric nephrotic syndrome: a clinical and histologic analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7787150" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Aggressive, long-term cyclosporine therapy for steroid-resistant focal segmental glomerulosclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11576878" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Long-term treatment of focal segmental glomerulosclerosis in children with cyclosporine given as a single daily dose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31749142" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Interventions for idiopathic steroid-resistant nephrotic syndrome in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8159300" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8808110" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18481113" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Cyclosporin A is superior to cyclophosphamide in children with steroid-resistant nephrotic syndrome-a randomized controlled multicentre trial by the Arbeitsgemeinschaft für Pädiatrische Nephrologie.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18039644" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Tacrolimus: a new therapy for steroid-resistant nephrotic syndrome in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19268410" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20217433" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Long-term outcome of children with steroid-resistant nephrotic syndrome treated with tacrolimus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19499248" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Experience with tacrolimus in children with steroid-resistant nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22714672" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Treatment of tacrolimus or cyclosporine A in children with idiopathic nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29515301" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Efficacy and Safety of Cyclosporine versus Tacrolimus in Steroid and Cyclophosphamide Resistant Nephrotic Syndrome: A Prospective Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21298518" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : The podocyte as a target: cyclosporin A in the management of the nephrotic syndrome caused by WT1 mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20848129" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Effect of cyclosporin A on proteinuria in the course of glomerulopathy associated with WT1 mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32651716" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Calcineurin inhibitors in nephrotic syndrome secondary to podocyte gene mutations: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20195644" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Non-immunologic mechanisms of calcineurin inhibitors explain its antiproteinuric effects in genetic glomerulopathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12811652" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Novel therapy of focal glomerulosclerosis with mycophenolate and angiotensin blockade.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12915830" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Long-term antiproteinuric and renoprotective efficacy and safety of losartan in children with proteinuria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14648339" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Enalapril dosage in steroid-resistant nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16773409" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Effect of fosinopril in children with steroid-resistant idiopathic nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15630898" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Mycophenolate mofetil in the treatment of focal segmental glomerulosclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15891923" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21319130" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Mycophenolate mofetil in treatment of childhood steroid-resistant nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19937060" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Mycophenolate mofetil in children with steroid/cyclophosphamide-resistant nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19953275" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Mycophenolate mofetil therapy for children with steroid-resistant nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28318625" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Mycophenolate mofetil is inferior to tacrolimus in sustaining remission in children with idiopathic steroid-resistant nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22581992" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Rituximab in steroid-resistant nephrotic syndrome in children: a (false) glimmer of hope?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19396468" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Fatal pulmonary fibrosis after rituximab administration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29680473" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Rituximab in The Management of Pediatric Steroid-Resistant Nephrotic Syndrome: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26101364" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Mycophenolate Mofetil Following Rituximab in Children With Steroid-Resistant Nephrotic Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30230027" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Remission of proteinuria in multidrug-resistant idiopathic nephrotic syndrome following immunoglobulin immunoadsorption.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21479767" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Novel multidrug therapy for children with cyclosporine-resistant or -intolerant nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9176855" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Treatment of the idiopathic nephrotic syndrome: regimens and outcomes in children and adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2206894" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Treatment of steroid-resistant focal segmental glomerulosclerosis with pulse methylprednisolone and alkylating agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7736683" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Intravenous methylprednisolone and oral alkylating agent therapy of prednisone-resistant pediatric focal segmental glomerulosclerosis: a long-term follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24500706" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Rituximab treatment combined with methylprednisolone pulse therapy and immunosuppressants for childhood steroid-resistant nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8897562" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis. A report of the International Study of Kidney Disease in Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22763815" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Treatment with tacrolimus and prednisolone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6488594" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Response to cyclophosphamide in steroid-resistant focal segmental glomerulosclerosis: a reappraisal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1911150" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Kidney biopsy prior to cyclophosphamide therapy in primary nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23052648" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Treatment of steroid-resistant nephrotic syndrome in children: new guidelines from KDIGO.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
